SCHEMBL5216133

SCHEMBL5216133

CC(C)(C)c1cccc(-n2cc(-c3cnc4ccccc4n3)cn2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.42
NPC1 O15118 8/20 0.42
RAB9A P51151 6/20 0.42
GRM4 Q14833 3/20 0.41
FGFR3 P22607 1/20 0.40
KDR P35968 1/20 0.40
EPHX2 P34913 1/20 0.40
MKNK1 Q9BUB5 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
BCHE P06276 1/20 0.39
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
TP53 P04637 1/20 0.39
STAT1 P42224 1/20 0.39
JAK2 O60674 1/20 0.39
HTR2B P41595 1/20 0.38
MTNR1A P48039 1/20 0.38
KCNH2 Q12809 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5256274 0.86 GRM5 (0.40) GRM5NPC1RAB9AGRM4EPHX2
SCHEMBL5215415 0.83 GRM2 (0.43) GRM5NPC1RAB9AGRM4EPHX2
SCHEMBL27091427 0.82 RAB9A (0.47) GRM5NPC1RAB9AGRM4EPHX2
SCHEMBL5216692 0.82 MKNK1 (0.57) NPC1RAB9AGRM4FGFR3KDR
SCHEMBL5216495 0.82 GRM4 (0.54) NPC1RAB9AGRM4SMN1; SMN2BCHE
SCHEMBL5217700 0.81 NPC1 (0.45) GRM5NPC1RAB9AGRM4FGFR3
SCHEMBL3917705 0.81 GRM5 (0.62) GRM5NPC1RAB9AGRM4KDR
SCHEMBL5217224 0.81 MKNK1 (0.52) GRM5NPC1RAB9AGRM4FGFR3
SCHEMBL30794399 0.81 GRM5 (0.62) GRM5NPC1RAB9AGRM4KDR
SCHEMBL8353703 0.81 BCHE (0.51) GRM5NPC1RAB9AGRM4FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458383-B1 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-11-21 EP claimed
EP-1458383-A4 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-05-25 EP claimed
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME LLC 2005-02-03 US claimed
EP-1458383-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 EP claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO claimed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO claimed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C GRM5 1/4885NPC1 4205/4885RAB9A 1352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.